Catalyst

Slingshot members are tracking this event:

Takeda Acquires U.S. Biologics Manufacturing Facility from Baxalta for the manufacture of Entyvio (vedolizumab)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TKPYY

100%

Additional Information

Additional Relevant Details The acquisition will also provide long-term strategic benefits for Takeda through enhanced capacities for the manufacture of additional commercial products and investigational drugs under clinical development. The plant allows Takeda to establish and develop direct commercial bio-manufacturing expertise. Terms of the transaction were not disclosed.
http://www.takeda.co...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 06, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Acquisition, Manufacturing, Entyvio, Vedolizumab